[16]. Han S, Iglay K, Davies MJ,et al. Glycemic effectiveness and medication adherence with fixed-dose combination or coadministered dual therapy of antihyperglycemic regimens:a meta-analysis[J]. Curr Med Res Opin, 2012, ...
[5]Han S,Iglay K,Davies MJ,et al.Glycemic effectiveness and medication adherence with fixed-dose combination or coadministered dual therapy of antihyperglycemic regimens:a meta-analysis[J].Curr Med Res Opin.2012,28(6):969-...
[14]Han S,Iglay K,Davies MJ,et al.Glycemic effectiveness and medication adherence with fixed-dose combination or coadministered dual therapy of antihyperglycemic regimens:a meta-analysis[J].Curr Med Res Opin.2012,28(6):969-77.DOI:10.1185/03007995.2012.684045. [15]Osterberg L,Blaschke T.Adher...
[5]Han S,Iglay K,Davies MJ,et al.Glycemic effectiveness and medication adherence with fixed-dose combination or coadministered dual therapy of antihyperglycemic regimens:a meta-analysis[J].Curr Med Res Opin.2012,28(6):969-77.DOI:10.1185/03007995.2012.684045. [6]Osterberg L,Blaschke T.Adheren...
编者按:近日,《钠-葡萄糖共转运蛋白2抑制剂(SGLT2i)联合二甲双胍治疗2型糖尿病(T2DM)专家共识》(以下简称“共识”)发表于《国际内分泌代谢杂志》。 2.肝功能受损:血清转氨酶超过3倍正常上限或有严…
编者按:近日,《钠-葡萄糖共转运蛋白2抑制剂(SGLT2i)联合二甲双胍治疗2型糖尿病(T2DM)专家共识》(以下简称“共识”)发表于《国际内分泌代谢杂志》。 2.肝功能受损:血清转氨酶超过3倍正常上限或有严…
In recent years, it has been found that SGLT2 is actually widely expressed in various tissues, such as pancreas and liver. The regulation effect of SGLT2i on energy metabolism is far beyond its effect in inhibiting the reabosption of glucose in the proximal tubule. Further learning of the...
We introduce the strengths and weaknesses of this medication and discuss unresolved issues that should be taken into considerations when prescribing SGLT2 inhibitors.Kim, Ji YoonKim, Sin GonJournal of Korean Diabetes
SGLT1 x SGLT2 作用机制 SGLT1抑制剂(钠-葡萄糖协同转运蛋白-1抑制剂)、SGLT2抑制剂(钠-葡萄糖协同转运蛋白-2抑制剂) 治疗领域 免疫系统疾病心血管疾病内分泌与代谢疾病 在研适应症 心脏衰竭非梗阻性肥厚型心肌病梗阻性肥厚型心肌病+ [2] 非在研适应症 ...
共识建议SGLT2i联合二甲双胍治疗的适用人群包括以下七类患者(表1): 新诊断T2DM患者 二甲双胍或SGLT2i单药治疗不达标的患者 其他种类降糖药单药治疗不达标的患者 T2DM患者合并动脉粥样硬化性心血管疾病(ASCVD)或其高危因素 T2DM患者合并HF T2DM合并慢性肾脏病(CKD)或糖尿病肾脏病(DKD)患者 ...